

Erratum to: Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer

Kate McKeage

Published online: 14 January 2015
© Springer International Publishing Switzerland 2015

Erratum to: Drugs (2015) 75:75–82
DOI 10.1007/s40265-014-0329-y

The author has alerted us to the following errors:

Page 79, column 2, paragraph 1, line 7.

The sentence that previously read:

‘A more recent review of this patient group (median follow-up 141 days) reported that 13 patients, four with prior brain irradiation, continued on study treatment without progression (reported in an abstract) [23].’

should read:

‘A more recent review of this patient group (median follow-up 141 days) reported that 13 patients, four without prior brain irradiation, continued on study treatment without progression (reported in an abstract) [23].’

Page 80, figure 4 legend, lines 5 and 6.

The figure legend that previously read:

‘Treatment-related adverse events associated with twice-daily alectinib 300 mg in patients with ALK-rearranged advanced non-small cell lung cancer. Adverse events reported in $\geq 10\%$ of patients ($n = 46$) in the phase 2 portion of a phase 1–2 study [18]. *ALP* alanine phosphatase, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *CPK* creatinine phosphokinase.’

should read:

‘Treatment-related adverse events associated with twice-daily alectinib 300 mg in patients with ALK-rearranged advanced non-small cell lung cancer. Adverse events reported in $\geq 10\%$ of patients ($n = 46$) in the phase 2 portion of a phase 1–2 study [18]. *ALP* alkaline phosphatase, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *CPK* creatinine phosphokinase.’

The online version of the original article can be found under doi:[10.1007/s40265-014-0329-y](https://doi.org/10.1007/s40265-014-0329-y).

K. McKeage (✉)
Springer, Private Bag 65901, Mairangi Bay 0754, Auckland,
New Zealand
e-mail: demail@springer.com